New experimental vaccine for Lou Gehrig’s disease gets EU funding

The EU has awarded Intravacc funding to develop an experimental vaccine for the neurodegenerative disease

Add bookmark
Women in wheelchair

Intravacc, a contract development and manufacturing organization (CDMO) and the German Center for Neurogenerative Diseases (DZNE), have received US$2.5 mn to develop a vaccine against a form of motor neuron disease.

The funding has been awarded by the European Union’s EIC Transition Grant and will be used to research a vaccine for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease also known as Lou Gehrig’s disease.

The project aims to develop a prototype ALS vaccine targeting the most common genetic ALS variant known as the C9orf72 gene, which causes between five and 10 percent of all ALS cases.

The investment will fund process development, scale-up and a toxicology study. Once the vaccine candidate is identified at DZNE, it will be clinically tested in humans.

Targeting gene mutations

ALS is triggered by protein aggregation in the brain and the spinal cord motor neurons that leads to paralysis and ultimately death, usually within two to five years.

Gene mutations have been identified as triggers for some forms of the disease, with a mutation in the C9orf72 gene being the most common. These mutations create toxic proteins called poly-Glycine-Alanine (poly-GA) that cause neurons to die.

DZNE has developed a vaccine that triggers an immune response to poly-GA, preventing them from replicating. Researchers believe that with regular vaccination, sufficient antibodies can be produced and maintained to reduce poly-GA levels. It is also hoped the vaccine could benefit those at risk of the disease as well as patients that develop related illnesses such as dementia.

The research is significant as there is currently no cure for motor neuron diseases. In the US alone it is estimated that there are 30,000 C9orf72 ALS cases, with 5,000 new cases diagnosed each year. An additional 9,000 mutation carriers who currently show no symptoms may be at risk of developing the illness.

The search for a cure

Despite its categorization as a rare illness, ALS is the most common type of motor neuron disease. It typically occurs in people between 40–70 years old, with men affected slightly more often than women.

Despite ongoing research, existing therapies can only alleviate symptoms rather than stop progression of the disease. There are two approved medications that can reduce symptoms: riluzole, currently marketed by Sanofi, and edaravone, sold by Mitsubishi Tanabe under the brand name Radicava.

A number of other studies are underway, among them research into a stem cell treatment called NurOwn, investigated by Brainstorm-Cell Therapeutics. While promising, at the end of its Phase III trial there was no significant difference between responses to NurOwn and responses to a placebo.

Commenting on Intravacc’s research into a new vaccine, its CEO Dr Jan Groen said: “There is an unmet need for effective, disease-modifying therapies to treat ALS patients. The goal of our current project is to develop the vaccine to the point where it can be tested in humans. Clinical trials for C9orf72 ALS are expected to commence in 2025.”

Quick links: 

Get exclusive access to member-only articles, reports, videos, interviews, webinars and other premium content from industry experts and thought leaders by signing up to Pharma IQ here


Upcoming Events

Cosmetic Compliance New York 2016

October 17 - 19, 2016

MANHATTAN NYC – An Affinia Hotel Collection, New York, NY

Cosmetic Compliance New York 2016

Pharma Traceability November - 2016

November 30 - December 2, 2016

Sheraton Philadelphia University City Hotel, Philadelphia, PA

Pharma Traceability November - 2016

UDIs and Traceability for Medical Devices

15 - 18 May, 2018

Pullman Brussels Centre Midi Hotel, Brussels, Belgium

UDIs and Traceability for Medical Devices

CRISPR: A New Era in Gene Editing

December 5 - 7, 2016

Embassy Suites by Hilton Boston at Logan Airport, Boston, MA

CRISPR: A New Era in Gene Editing

10. Jahreskonferenz Pharma Packaging 2016

29 February - 2 March, 2016

Golden Tulip Berlin - Hotel Hamburg, Berlin, Germany

10. Jahreskonferenz Pharma Packaging 2016

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended